DCTH: Delcath Price to Sales

Symbol and logo of brand Delcath Corp (DCTH)

The investment potential of Delcath Systems, Inc. (DCTH) is based on management's determination to successfully commercialize innovative oncology systems. The price-to-sales ratio dynamics illustrate this trend, where the value of 6.70 captures the metric level. This growth is supported by the expansion of Hepzato into US clinics, featuring high-margin consumables and the exclusive right to exercise pricing power for the treatment of rare metastases.

Delcath Systems - DCTH P/S Multiple (period 07/04/2022 - 11/13/2026)

Delcath (DCTH) - metric breakdowns and financial figures

- stock price and consensus target price:
Share Price delcath.com|DCTH - Analyst Consensus Forecast
- market capitalization information:
Market Value Delcath|DCTH - Total Company Value
- shareholders' equity book value data:
Net Assets per Single Share Delcath Systems|DCTH - Book Capitalization|Market Cap to Net Assets Ratio delcath.com|DCTH - Company Total Assets
- issuer credit burden and liquidity indicators:
Total Debt to Capital Delcath Systems, Inc.|DCTH - Long-Term Debt to Equity Ratio|Short-Term Loans to Capital Ratio Delcath Corp|DCTH - Company Aggregate Debts|Debt to Net Assets Ratio Delcath|DCTH - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings Delcath Systems|Interim Coverage Ratio delcath.com
- financial results and valuation multiples details:
DCTH - Net Income|Expected Net Profit Delcath Systems, Inc.|DCTH - Price to Earnings Ratio|Market Cap to Projected Earnings Delcath Systems Inc|DCTH - Price/Earnings to Growth Multiple|Enterprise Value to Operating Income Before Depreciation Ratio Delcath|DCTH - Operating profit EBITDA|Net earnings per one share for the last twelve months Delcath Systems|DCTH - Earnings per share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months delcath.com|DCTH - Earnings per share growth in current year|Consensus forecast of earnings per share growth for next year Delcath Systems, Inc.
- issuer revenue and sales details:
DCTH - Company Sales|Company Future Revenue delcath.com|DCTH - P/S Multiple|Market Cap to Expected Sales Ratio Delcath
General company analysis:delcath.com, DCTH
Signature product of Delcath Systems Inc

The business stability of Delcath Systems, Inc. (DCTH) depends on the commercialization pace of the HEPZATO KIT for hepatic chemical perfusion. By analyzing P/S ratio volatility, an investor compares market capitalization with actual sales volume, which allows for the identification of asset overvaluation or company undervaluation relative to its revenue, thereby determining the fair value of shares within the context of the biotechnology sector.

Who Delcath Systems, Inc. competes with

beigene.com - Market Cap to Revenue Ratio|P/S Multiple HALO (Halozyme)|Revolution Medicines Inc (RVMD) - Price to Sales|AAPG - Price-to-Revenue Ratio|CGON: Price-to-Revenue Ratio|URGN: P/S Multiple|Market Cap to Revenue bicara.com|PSNL (Personalis) - P/S Multiple|P/S Multiple Erasca Inc|Market Cap to Revenue YMAB (YmAbs)|Market Cap to Sales Volume AURA|P/S Multiple CADL (Candel Therapeutics, Inc.)|Market Capitalization-to-Revenue Ratio ARAY|SLS: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio ACTU (Actuate Therapeutics Inc.)|Citius Oncology, Inc (CTOR) - Price-to-Revenue Ratio|HURA - Price-to-Revenue Coefficient|Market Cap to Revenue TARA|Price to Sales fatetherapeutics.com FATE|Price-to-Revenue Ratio Aadi Bioscience Inc (WHWK)|Price-to-Revenue Coefficient tscan.com|Champions Oncology, Inc. - Market Cap to Revenue|Market Cap to Sales Volume XBIT (XBiotech Inc)|CEL-SCI Corp - P/S Multiple|Price to Sales ostherapies.com|Radiopharm Theranostics (RADX) - Price-to-Revenue Ratio|Market Cap to Revenue Artiva Biotherapeutics|Price-to-Revenue Ratio Adlai Nortye Ltd|Veru Corporation (VERU) - Price-to-Revenue Coefficient|Market Cap to Revenue TPST (Tempest Therapeutics)|XLO (xiliotx.com) - Market Capitalization-to-Revenue Ratio|P/S Multiple RENB (Renovaro)|Price-to-Revenue Coefficient Mural Oncology PLC (MURA)|KAPA - Price-to-Revenue Ratio|OKUR (OnKure Therapeutics Inc) - Market Cap to Revenue Ratio|GDTC: P/S Multiple|Market Cap to Revenue Curis|Market Cap to Revenue APLM|Tharimmune Inc (THAR) - Price-to-Revenue Coefficient|P/S Multiple ADVB|Genprex Inc - Market Cap to Revenue Ratio|P/S Multiple CLDI (Calidi Biotherapeutics, Inc.)|SBFM - Market Cap to Revenue|XBIO: Market Cap to Revenue|Salarius Pharmaceuticals Inc - Market Cap to Sales Volume|PPBT: P/S Multiple|American Oncology Network, Inc. - Market Capitalization-to-Revenue Ratio|BGNE (BeiGene, Ltd.) - P/S Multiple|Market Cap to Revenue checkpointtx.com (CKPT)|P/S Multiple ELEV|P/S Multiple icadmed.com (ICAD)|Price-to-Revenue Ratio Ikena Oncology IKNA|NTBL: Market Cap to Revenue Ratio|Viracta - P/S Multiple|morphosys.com (MOR) - Market Cap to Revenue|NAYA: P/S Multiple|Price to Sales Ascentage Pharma Group International (AAPGV)